

European Meeting on Protein Arginine Methyltransferases in Cancer



*Centre George François Leclerc - Dijon
28th and 29th September, 2023*

1 Rue du Professeur Marion, 21000 Dijon
T1 tram to "CHU – Hôpitaux"
or L3 bus to "CHU – Hôpitaux"

European Meeting on PRMTs in Cancer

28th and 29th September 2023 - Provisional program

Thursday, 28th

12:30 pm – 1:30 pm Welcome cocktail

1:30 pm – 1:40 pm **Laurent Delva, François Ghiringhelli, Marc Maynadié**

Session 1 chairs: Mary Callanan & Fabien Guidez

1:40 pm – 2:20 pm **Uta-Maria Bauer** (Marburg, Germany)

PRMTs: important players in human malignancy

2:20 pm – 3:00 pm **Clare Davies** (Birmingham, England, UK)

Understanding the role of PRMTs in the DNA damage response

3:00 pm – 3:40 pm **Thierry Dubois** (Paris, France)

PRMTs as potential therapeutic targets for triple-negative breast cancers

3:40 pm – 4:20 pm **Muriel Le Romancer** (Lyon, France)

Role of PRMTs in breast cancer

4:20 pm – 5:00 pm Coffee break and Poster session

5:00 pm – 5:40 pm **Engin Demirdizen** (Göttingen, Germany)

Identifying therapeutic vulnerabilities for pancreatic cancer treatment

5:40 pm – 6:20 pm **Tiziana Bonaldi** (Milano, Italy)

Multi-layer regulation of adaptive response to chemotherapy by PRMT1 in ovarian cancer: a proteomic perspective

European Meeting on PRMTs in Cancer

28th and 29th September 2023 - Provisional program

Friday, 29th

9:00 am – 9:30 am Welcome breakfast

Session 2 chairs: Emeric Limagne & Camille Sauter

9:30 am – 10:10 am **Romain Aucagne** (Dijon, France)

PRMT2 is involved in acute myeloid leukemia through its role on inflammation

10:10 am – 10:50 am **Paola Arimondo** (Paris, France)

AntiDOTes for diseases: Chemistry and biology match together to tackle epigenetics

10:50 am – 11:30 am Coffee break and Poster session

11:30 am – 12:10 pm **Vincent Cura** (Illkirch-Graffenstaden, France)

Functional insights from the structures of different PRMTs

12:10 pm – 12:50 pm **Nathaniel Martin** (Leiden, Netherlands)

Nicotinamide N-methyltransferase (NNMT): An emerging & unexploited target in metabolic disease and cancer

12:50 pm End of the meeting